BridgeBio Pharma, Inc.

Total revenues were $243.7 million for Q2 2026, up from $110.6 million in Q2 2025. Attruby net product revenue was $222.4 million versus $71.5 million a year ago; royalty revenue was $15.4 million versus $1.6 million; and license and services revenue was $5.8 million versus $37.4 million. Total operating expenses were $335.7 million versus $241.2 million last year, and the operating loss was $107.1 million compared with a $134.3 million loss in Q2 2025. As of June 30, 2026, cash, cash equivalents, and marketable securities were $720.2 million, and after the July 1 $1 billion preferred equity financing, cash was approximately $1.7 billion. Management did not provide formal revenue or EPS guidance on the call, but said Attruby remains on track for continued steady sales growth, and that BridgeBio believes its current cash position supports operating needs and three potential launches over the next 12 months.

Neil Kumar framed the quarter as a transition point for BridgeBio, saying the company is at “t equals zero” in its next chapter. He emphasized a stronger Attruby launch story built on clinical differentiation, real-world evidence, and newly published kidney-protection data, and said these could support broader use over the next 6 to 9 months. He also highlighted the broader pipeline, saying all three late-stage programs are now in regulatory review and that the company has a substantial set of future shots on goal.

Tom Trimarchi focused on the financial buildout behind the commercial expansion. He cited $243.7 million in revenue, $222.4 million in Attruby net product revenue, and a $107.1 million operating loss that improved about 20% year over year despite $335.7 million of operating expenses tied to launch preparation. He also noted $720.2 million in cash at quarter-end, followed by a $1 billion preferred equity investment led by Sixth Street, taking cash to about $1.7 billion and providing runway for three launches and continued Attruby investment.

Analysts focused heavily on how CARDIO-TTRansform affects Attruby’s position. Management said the failure of combination therapy supports stabilizers as the backbone of treatment, and Neil Kumar argued the data should enlarge the frontline pool while further reinforcing Attruby versus both knockdowns and tafamidis. Questions also centered on the kidney data, pricing, and market share assumptions; management said it does not plan to chase Pfizer on rebates, prefers clinical differentiation over price cuts, and will revisit market-share expectations after more complete CARDIO-TTRansform data and the ESC meeting. Additional questions covered launch readiness for BBP-418 and encaleret, ex-U.S. commercialization, and infigratinib’s achondroplasia market, with management emphasizing strong FDA interactions, payer interest, and confidence in global launches.